<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Immunol. Immunother</journal-id><journal-title-group><journal-title>Cancer Immunology, Immunotherapy</journal-title></journal-title-group><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22113713</article-id><article-id pub-id-type="pmc">3362718</article-id><article-id pub-id-type="publisher-id">1159</article-id><article-id pub-id-type="doi">10.1007/s00262-011-1159-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The additional value of TGF&#x003b2;1 and IL-7 to predict the course of prostate cancer progression</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Schroten</surname><given-names>Caroline</given-names></name><address><email>schroten@ikr.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dits</surname><given-names>Natasja F.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Steyerberg</surname><given-names>Ewout W.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kranse</surname><given-names>Ries</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>van Leenders</surname><given-names>Arno G. J. L. H.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bangma</surname><given-names>Chris H.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kraaij</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Urology, ErasmusMC, Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands </aff><aff id="Aff2"><label>2</label>Department of Public Health, ErasmusMC, Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands </aff><aff id="Aff3"><label>3</label>Comprehensive Cancer Centre, Rotterdam, The Netherlands </aff><aff id="Aff4"><label>4</label>Department of Pathology, ErasmusMC, Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>11</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>11</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2012</year></pub-date><volume>61</volume><issue>6</issue><fpage>905</fpage><lpage>910</lpage><history><date date-type="received"><day>27</day><month>7</month><year>2011</year></date><date date-type="accepted"><day>6</day><month>11</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2011</copyright-statement></permissions><abstract id="Abs1"><sec><title>Background</title><p>Given the fact that prostate cancer incidence will increase in the coming years, new prognostic biomarkers are needed with regard to the biological aggressiveness of the prostate cancer diagnosed. Since cytokines have been associated with the biology of cancer and its prognosis, we determined whether transforming growth factor beta 1 (TGF&#x003b2;1), interleukin-7 (IL-7) receptor and IL-7 levels add additional prognostic information with regard to prostate cancer-specific survival.</p></sec><sec><title>Materials and methods</title><p>Retrospective survival analysis of forty-four prostate cancer patients, that underwent radical prostatectomy, was performed (1989&#x02013;2001). Age, Gleason score and pre-treatment PSA levels were collected. IL-7, IL-7 receptor and TGF&#x003b2;1 levels in prostate cancer tissue were determined by quantitative real-time RT-PCR and their additional prognostic value analyzed with regard to prostate cancer survival. Hazard ratios and their confidence intervals were estimated, and Akaike&#x02019;s information criterion was calculated for model comparison.</p></sec><sec><title>Results</title><p>The predictive ability of a model for prostate cancer survival more than doubled when TGF&#x003b2;1 and IL-7 were added to a model containing only the Gleason score and pre-treatment PSA (AIC: 18.1 and AIC: 6.5, respectively).</p></sec><sec><title>Conclusion</title><p>IL-7 and TGF&#x003b2;1 are promising markers to indicate those at risk for poor prostate cancer survival. This additional information may be of interest with regard to the biological aggressiveness of the diagnosed prostate cancer, especially for those patients screened for prostate cancer and their considered therapy.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Gleason score</kwd><kwd>Interleukin-7</kwd><kwd>Prostate cancer</kwd><kwd>Survival</kwd><kwd>TGF&#x003b2;1</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2012</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>According to UN Projections, the population aged 60 or over increases from 475&#x000a0;million in 2009 to 1.6&#x000a0;billion in the year 2050. Since prostate cancer is primarily a disease of elderly males, one could expect an increase of prostate cancer incidence in the coming years. In addition, an extra increase could be expected as a consequence of screening for prostate cancer, for example, using prostate-specific antigen (PSA) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>].</p><p>Histologic tumor grading of prostate cancer is essential for the assessment of prognosis. Prognosis refers to the expected biologic potential of a patient&#x02019;s prostate cancer to spread to other organs, that is, to metastasize. Prognosis is, among others, based upon PSA pre-treatment level and the Gleason score. The Gleason grading system uses the histological pattern of neoplastic cells in hematoxylin-eosin-stained sections and is largely subjectively scored by the pathologist [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>Gleason scores can be derived from both biopsy and radical prostatectomy samples. The biopsy-derived Gleason score often undergrades the Gleason score of the actual tumor because of sampling error [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore, a high variability has been described in the way clinicians use prostate needle biopsy-based pathology reports [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Despite the inter and intraobserver variabilities of Gleason score determination, and discordance in the Gleason score between biopsy and radical prostatectomy specimens, the Gleason score remains the most important prognostic factor for prostate cancer clinical outcome and therefore strongly influences decisions regarding options for therapy [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The above limitations of the Gleason score indicate the need for additional, and preferably objectively measured information on the biological aggressiveness of the diagnosed prostate cancer, especially while screening for prostate cancer.</p><p>Cytokines have been associated with the biology of cancer and its prognosis. These low molecular weight molecules have significant roles, not only in immune/inflammatory systems, but also in hematopoiesis, the acute phase response, and multiple other functions. Specific cytokines have been found to be elevated in plasma of patients with various malignancies including prostate cancer. For example, earlier studies suggested a relation between increased levels of interleukin-4 (IL-4), IL-6 and IL-10 with prostate malignancy [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Other studies reported patients with metastatic prostate cancer which were associated with increased transforming growth factor beta (TGF&#x003b2;) serum levels, and TGF&#x003b2;1 accumulation in primary and metastatic prostate cancer tissue samples [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. Furthermore, an antagonistic relationship has been suggested for TGF&#x003b2; and IL-7. TGF&#x003b2; down regulates IL-7 secretion [<xref ref-type="bibr" rid="CR19">19</xref>], whereas IL-7 inhibits the production of TGF-beta1 by tumor cells [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>In non-cancer cells, TGF&#x003b2; stops cell proliferation, induces differentiation, or promotes apoptosis. In cancer cells, mutations of the TGF&#x003b2; pathway confer resistance to growth inhibition by TGF&#x003b2;, resulting in uncontrolled cell proliferation. The increase of TGF&#x003b2; production in cancer cells also stimulates angiogenesis and suppresses the activities of infiltrating immune cells, thereby facilitating the tumor to escape immunosurveillance [<xref ref-type="bibr" rid="CR21">21</xref>]. On the other hand, IL-7 promotes T cell cytolytic, innate responses, antitumor reactivity in lung cancer, and prolonged survival in mice after whole cell vaccination with cells that are able to secrete mIL-7 [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. Loss of epithelial IL-7 in prostate cancer tissue is associated with a severe depletion of prostate-associated lymphocytes [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p>Therefore, we hypothesize that TGF&#x003b2;1, the IL-7 receptor and IL-7 may add additional objective information to Gleason score and pre-treatment PSA level-based prognosis of prostate cancer-specific survival. In this retrospective study in forty-four patients with localized prostate cancer who underwent radical prostatectomy, we tested this working hypothesis. Prostate cancer-specific survival was examined in relation to the Gleason score, pre-treatment PSA level, age, and prostate tissue expression levels of IL-7, TGF&#x003b2;1 and the IL-7 receptor.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Patient samples</title><p>Clinical prostate cancer samples (1989&#x02013;2001) were obtained from the tissue bank of the Erasmus University MC. Samples were snap frozen and stored in liquid nitrogen. All samples contained at least 70% tumor cells. Collection of patient samples was performed according to national legislation concerning ethical requirements. The Erasmus MC Medical Ethics Committee, according to the Medical Research Involving Human Subjects Act, approved the use of these samples. Population characteristics are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, follow-up was completed until December 31, 2008.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Characteristics of forty-four patients with localized prostate cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Continuous</th><th align="left">Log-transformed</th></tr></thead><tbody><tr><td align="left">Age at treatment, median (IQR)</td><td align="left">61.0 (9.5)</td><td char="(" align="char"/></tr><tr><td align="left">PSA pre-treatment (ng/ml), median (IQR)</td><td align="left">10.8 (13.8)</td><td char="(" align="char">3.4 (1.6)</td></tr><tr><td align="left">Cancer percentage in tissue, median (IQR)</td><td align="left">90.0 (1.0)</td><td char="(" align="char"/></tr><tr><td align="left" colspan="3">Gleason score (n)</td></tr><tr><td align="left">&#x000a0;6</td><td align="left">29</td><td char="(" align="char"/></tr><tr><td align="left">&#x000a0;7</td><td align="left">10</td><td char="(" align="char"/></tr><tr><td align="left">&#x000a0;8&#x02013;10</td><td align="left">5</td><td char="(" align="char"/></tr><tr><td align="left" colspan="3">Cytokine tissue levels (expression/PBDG)</td></tr><tr><td align="left">&#x000a0;IL-7</td><td align="left">6.0 (6.0)</td><td char="(" align="char">2.6 (1.3)</td></tr><tr><td align="left">&#x000a0;IL-7r</td><td align="left">3.4&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup> (7.2&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup>)</td><td char="(" align="char">25.0 (2.5)</td></tr><tr><td align="left">&#x000a0;TGF&#x003b2;1</td><td align="left">44.5 (48.5)</td><td char="(" align="char">5.5 (1.4)</td></tr></tbody></table><table-wrap-foot><p>Cytokine levels determined in prostate cancer tissues of the 44 prostate cancer patients studied. <italic>IL</italic>-<italic>7</italic> interleukin 7, <italic>IL</italic>-<italic>7r</italic> interleukin 7 receptor, <italic>TGF&#x003b2;1</italic> tumor growth factor beta 1, <italic>PSA</italic> prostate-specific antigen, <italic>IQR</italic> interquartile range</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>RNA isolation and gene expression analysis</title><p>RNA from the prostate cancer samples was using RNABee reagent as described by the manufacturer (Tel-test, Inc., Friendswood, TX, USA). The RT reaction was performed with 1&#x000a0;&#x003bc;g RNA from the samples with oligo-(dT)<sub>12&#x02013;18</sub> primer (Invitrogen) and pre-incubated for 10&#x000a0;min at 70&#x000b0;C. First-strand buffer, dithiothreitol, dNTPs and RNAsin were added and incubated for 2&#x000a0;min at 37&#x000b0;C. The RT reaction was initiated by MMLV-RT and incubated for 1&#x000a0;h at 37&#x000b0;C. After this, the reaction was maintained for 10&#x000a0;min at 90&#x000b0;C and immediately thereafter frozen. Quantitative real-time RT-PCR analysis was done with an ABI Prism 7700 Sequence Detection System (Applied Biosystems) using AmpliTaq Gold according to the manufacturer&#x02019;s specifications (Applied Biosystems, Foster City, CA). The FAM-labeled primers and probes for Taqman Gene Expression Assays were obtained from Applied Biosystems (IL-7, Hs00978525_m1; IL-7receptor, Hs00902334_m1; TGFbeta1, Hs00998133_m1). The CT readings of target gene expressed were normalized to an endogenous reference and relative to a calibrator. The endogenous reference was <italic>Porphobilinogen deaminase</italic> (PBDG); a mixture of cDNAs of prostate carcinoma xenografts was used as the calibrator [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec5"><title>Statistics</title><p>With death from prostate cancer as event, and death from other causes considered as censored events, log-rank tests and Cox regressions were performed using base 2 log-transformed pre-treatment PSA levels, and base 2 log-transformed IL-7, IL-7receptor and TGF&#x003b2;1 relative expression levels. Post-surgical information such as pTNM staging was omitted in this study because of our interest in a possible stronger pre-surgical prognosis, at present mainly based upon the pre-treatment PSA levels and the Gleason score. The relation of the variables on prostate cancer survival was determined, along with Akaike&#x02019;s information criterion (AIC<sub arrange="stack"><italic>X</italic></sub><sup arrange="stack">2</sup>) for the comparison of the models. The AIC<sub arrange="stack"><italic>X</italic></sub><sup arrange="stack">2</sup> measures the improvement in prognostic value of a model with respect to a model with a sole constant as a predictor (=null-model). Therefore, if two models are compared (using the same underlying dataset), the model with the highest AIC<sub arrange="stack"><italic>X</italic></sub><sup arrange="stack">2</sup> is to be preferred. Please note that AIC is different than the mentioned AIC<sub arrange="stack"><italic>X</italic></sub><sup arrange="stack">2</sup>. AIC is defined as the &#x02212;2log likelihood of the observed data at hand under the assumed model, corrected for the number of degrees of freedom. It refers to the quality of the fit. A perfect fit yields a &#x02212;2log likelihood of zero, a less than perfect fit a value greater than zero, and therefore the smaller the AIC the better the fit.</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results</title><sec id="Sec7"><title>Patient characteristics</title><p>Forty-four prostate cancer patients were studied, 7 patients died of prostate cancer. All patients underwent radical prostatectomy and had clinical findings reviewed. Patient characteristics and relative cytokine expression levels are reported in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The median age at diagnosis was 61&#x000a0;years with an interquartile range (IQR) of 9.5&#x000a0;years. The median PSA level pre-treatment was 10.8&#x000a0;ng/ml (IQR: 13.8&#x000a0;ng/ml), and the median Gleason score was 6. Median cytokine levels in the examined prostate cancer tissue samples were 6.0 (IQR: 6.0), 3.4&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup> (IQR 7.2&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup>) and 44.5 (IQR 48.5) for IL-7, IL-7receptor and TGF&#x003b2;1, respectively. The median follow-up time was 11.8&#x000a0;years (IQR 5.3&#x000a0;years) after radical prostatectomy.</p></sec><sec id="Sec8"><title>Analysis of prostate cancer-specific survival</title><p>First a log-rank test was performed using the individual variables in relation with prostate cancer-specific survival. Both the Gleason score (<italic>P</italic>&#x000a0;=&#x000a0;0.00) and pre-treatment PSA levels (<italic>P</italic>&#x000a0;=&#x000a0;0.00) did show a relation with prostrate cancer-specific survival, as well as IL-7 receptor (<italic>P</italic>&#x000a0;=&#x000a0;0.00), IL-7 (<italic>P</italic>&#x000a0;=&#x000a0;0.04) and TGF&#x003b2;1 (<italic>P</italic>&#x000a0;=&#x000a0;0.00). Age at diagnosis (<italic>P</italic>&#x000a0;=&#x000a0;0.91) did not indicate to be related to prostate cancer death. Contribution of separate variables to prostate cancer-specific survival is summarized in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Univariate analysis of individual variables with regard to prostate cancer survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><italic>X</italic><sup>2</sup></th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">Gleason score</td><td char="." align="char">47</td><td char="." align="char">0.00</td></tr><tr><td align="left">Pre-treatment PSA</td><td char="." align="char">102</td><td char="." align="char">0.00</td></tr><tr><td align="left">TGF&#x003b2;1</td><td char="." align="char">100</td><td char="." align="char">0.00</td></tr><tr><td align="left">IL-7</td><td char="." align="char">26</td><td char="." align="char">0.04</td></tr><tr><td align="left">IL-7receptor</td><td char="." align="char">102</td><td char="." align="char">0.00</td></tr><tr><td align="left">Age</td><td char="." align="char">26</td><td char="." align="char">0.13</td></tr></tbody></table><table-wrap-foot><p>The variables IL-7 expression, IL-7 receptor expression, TGF&#x003b2;1 expression and pre-treatment PSA levels were base 2 log-transformed before analysis. <italic>IL</italic>-<italic>7</italic> interleukin 7, <italic>IL</italic>-<italic>7r</italic>&#x000a0;=&#x000a0;interleukin 7 receptor, <italic>TGF&#x003b2;1</italic> tumor growth factor beta 1, <italic>PSA</italic> prostate-specific antigen</p></table-wrap-foot></table-wrap></p><p>Secondly, multivariate analysis with regard to prostate cancer-specific survival was performed (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The basic model included the Gleason score (hazard ratio (HR) 2.4, confidence interval (CI) 1.0&#x02013;6.1) and PSA levels pre-treatment (HR 1.4 CI 0.8&#x02013;2.2), since these two parameters are, among others, used for decision-making on prostate cancer treatment. This basic model was extended using the other variables. Extending the basic model with basic model with the variables IL-7receptor (HR 0.52 CI 0.22&#x02013;1.20) or age (HR 0.96 CI 0.85&#x02013;1.09) did not improve the prediction of disease specific survival. The best model for prediction of disease-specific survival included the log-transformed pre-treatment PSA levels (HR 1.6 CI 0.8&#x02013;3.0), log-transformed TGF&#x003b2;1 expression (HR 10.4 CI 2.1&#x02013;52.0), log-transformed IL-7 expression (HR 0.1 CI 0.0&#x02013;0.9) and the Gleason score (HR 4.2 CI 1.0&#x02013;17.7). The AIC<sub arrange="stack"><italic>X</italic></sub><sup arrange="stack">2</sup> were 6.5 and 18.1 for the basic model and the final model, respectively.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Multivariate analysis using Cox regression of the basic model, including pre-treatment PSA levels and Gleason score</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">Multivariate basic model</th><th align="left" colspan="3">Multivariate final model</th></tr><tr><th align="left">HR</th><th align="left">CI</th><th align="left"><italic>P</italic>-value</th><th align="left">HR</th><th align="left">CI</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">Gleason score</td><td char="." align="char">2.4</td><td align="left">0.97&#x02013;6.11</td><td char="." align="char">0.06</td><td char="." align="char">4.2</td><td align="left">1.01&#x02013;17.68</td><td align="left">0.05</td></tr><tr><td align="left">Pre-treatment PSA</td><td char="." align="char">1.4</td><td align="left">0.85&#x02013;2.22</td><td char="." align="char">0.20</td><td char="." align="char">1.6</td><td align="left">0.80&#x02013;3.04</td><td align="left">0.19</td></tr><tr><td align="left">TGF&#x003b2;1</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">10.4</td><td align="left">2.01&#x02013;52.00</td><td align="left">0.00</td></tr><tr><td align="left">IL-7</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.1</td><td align="left">0.02&#x02013;0.86</td><td align="left">0.03</td></tr></tbody></table><table-wrap-foot><p>This basic model was extended using the log-transformed IL-7 expression and TGF&#x003b2;1 expression for the best prediction of disease specific survival. The AIC<sub arrange="stack"><italic>X</italic></sub><sup arrange="stack">2</sup> were 6.5 and 18.1 for the basic model and the final model, respectively. <italic>IL</italic>-<italic>7</italic> interleukin 7, <italic>TGF&#x003b2;1</italic> tumor growth factor beta 1, <italic>PSA</italic> prostate-specific antigen, <italic>HR</italic> hazard ratio, <italic>CI</italic> confidence interval</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec9" sec-type="discussion"><title>Discussion</title><p>We analyzed the data of forty-four prostate cancer patients for prostate cancer-specific survival in relation with the Gleason score, PSA-level pre-treatment, age at diagnosis, and the expression levels of IL-7, TGF&#x003b2;1 and the IL-7 receptor within prostate cancer tissue samples.</p><p>Besides the Gleason scores and pre-treatment PSA levels, also the IL-7 receptor, IL-7 and TGF&#x003b2;1 were related to prostate cancer-specific survival (log-rank test, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The relation of the Gleason score and PSA levels with prostate cancer prognosis has been reported since the 1960s [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Elevated levels of TGF&#x003b2;1 are associated earlier to be involved in the development of prostate cancer in animal models and accumulation of TGF&#x003b2;1 in primary and metastatic prostate cancer tissue samples [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. Pre-treatment biomarker levels of for example vascular endothelial growth factor, IL-6 but also TGF&#x003b2;1 have been indicated to improve the accuracy of post-prostatectomy for prediction of biochemical recurrence, when incorporated into standard predictive models. It was suggested that this incorporation might allow more accurate identification of patients who are likely to fail RP thereby allowing more efficient delivery of adjuvant therapy [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. It has however also been reported that plasma TGF&#x003b2;1 was not elevated in prostate cancer patients compared to non-prostate cancer patients. Plasma TGF&#x003b2;1 levels did not correspond to Gleason score or PSA levels in these patients; however, urinary TGF&#x003b2;1 levels did [<xref ref-type="bibr" rid="CR32">32</xref>]. On the other hand, one should take into account that urinary markers might reflect a renal process rather than a prostate cancer process, as well as the variation of serum markers due to underlying disease or age [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>]. Even though it is difficult to compare these studies because different methods were used in collection and preparation of patient samples, more objective TGF&#x003b2;1 detection in plasma or other cytokines related to prostate cancer could ease in determination of the prostate cancer process and treatment. Decreased IL-7receptor expression has not been reported before in relation with prostate cancer tissue. However, reduced numbers of IL-7 receptor expressing immune cells and IL-7-signaling defects in peripheral blood were observed in patients with breast cancer [<xref ref-type="bibr" rid="CR36">36</xref>]. Epithelial IL-7 production was reported to support intraprostatic lymphocyte survival. Its loss in prostate cancer is associated with a severe depletion of prostate-associated lymphocytes and points to a tumor escape mechanism [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p>Functional cytokines are classified in pro-inflammatory (Th1) and anti-inflammatory (Th2). It has been reported that high levels of the anti-inflammatory cytokines IL-4 and IL-10 are associated with elevated levels of PSA [<xref ref-type="bibr" rid="CR13">13</xref>]. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. In relation to prostate cancer, elevated levels of IL-6 have been associated with elevated levels of PSA and disease activity [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. TGF&#x003b2;1 also belongs to the anti-inflammatory cytokines, and in relation with prostate cancer, elevated levels of TGF&#x003b2;1 were correlated to disease progression [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>], which is also observed in our presented model. IL-7, on the other hand, is a pro-inflammatory cytokine. In our model, low levels of IL-7 are associated with poor prostate cancer survival, which reflects the suggested antagonistic relationship between TGF&#x003b2; and IL-7 [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. The overall picture for prostate cancer suggests that elevation of anti-inflammatory cytokines is related to poor prostate cancer prognosis, while elevation of pro-inflammatory cytokines reduces the risk [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>].</p><p>Multivariate models based on the Gleason score and pre-treatment PSA levels extended with other variables have been validated in this study. The final model for prediction of prostate cancer-specific survival included the Gleason score, pre-treatment PSA levels, TGF&#x003b2;1 expression and IL-7 expression. When Cox regression was performed, hazard ratios, together with their confidence intervals, were presented (<italic>P</italic>-values lower or equal to 0.05 were considered statistically significant), along with Akaike&#x02019;s information criterion (AIC<sub arrange="stack"><italic>X</italic></sub><sup arrange="stack">2</sup>). A model with base 2 log-transformed variables showed better fitting (observed-expected) compared to non-log-transformed variables (AIC<sub arrange="stack"><italic>X</italic></sub><sup arrange="stack">2</sup>: 18.05 and 15.89, respectively).</p><p>The additional value of TGF&#x003b2;1 and IL-7 with respect to predicting the natural course of disease was evident, since the prognostic value of the model was almost three times higher than a model including only Gleason score and pre-treatment PSA (AIC<sub arrange="stack"><italic>X</italic></sub><sup arrange="stack">2</sup> 18.1 vs. AIC<sub arrange="stack"><italic>X</italic></sub><sup arrange="stack">2</sup> 6.5, respectively). This model also reflects the suggested antagonistic behavior of TGF&#x003b2;1 and IL-7. High levels of TGF&#x003b2;1 corresponded with a higher risk, and high IL-7 levels with reduced risk of prostate cancer death. Given the limitations of Gleason grading, the final model was analyzed without the Gleason score (data not shown). This model showed to be less predictive for prostate cancer survival, and the AIC<sub arrange="stack"><italic>X</italic></sub><sup arrange="stack">2</sup> was lower (AIC 13.5) compared to the final model including the Gleason score (AIC 18.1). Therefore, it was concluded that the predictive value of Gleason score, despite its limitations, could not be omitted in a predictive model for prostate cancer survival.</p><p>Given the limited number of patients in this study, these results need to be externally validated in studies with larger prostate cancer patient populations [<xref ref-type="bibr" rid="CR39">39</xref>]. Nevertheless, our results indicate that IL-7 and TGF&#x003b2;1 are promising markers to indicate those patients at risk for poor survival. Objectively measured TGF&#x003b2;1 and IL-7 expression levels in prostate cancer tissues can be of additional value with respect to the biological aggressiveness of the diagnosed prostate cancer and the considered therapy, when incorporated into a predication model containing the Gleason score and pre-treatment PSA levels. If pre-surgical TGF&#x003b2;1 and IL-7 expression levels could be measured in serum or urine [<xref ref-type="bibr" rid="CR32">32</xref>], with the same predictive properties as TGF&#x003b2;1 and IL-7 derived from prostate cancer tissue, the application of the former is likely to be preferred.</p></sec></body><back><ack><p>The authors thank Dr. R.A. Willemsen, Prof. T.H. van der Kwast, G. Jenster and Prof. S.M. Todryk for their critical reading and feedback.</p><sec id="d29e1008"><title>Conflict of interest</title><p>The authors declare that they have no conflict of interest.</p></sec><sec id="d29e1013"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckersberger</surname><given-names>E</given-names></name><name><surname>Finkelstein</surname><given-names>J</given-names></name><name><surname>Sadri</surname><given-names>H</given-names></name><name><surname>Margreiter</surname><given-names>M</given-names></name><name><surname>Taneja</surname><given-names>SS</given-names></name><name><surname>Lepor</surname><given-names>H</given-names></name><name><surname>Djavan</surname><given-names>B</given-names></name></person-group><article-title>Screening for prostate cancer: A review of the ERSPC and PLCO trials</article-title><source>Rev Urol</source><year>2009</year><volume>11</volume><fpage>127</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">19918338</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroder</surname><given-names>FH</given-names></name><name><surname>Hugosson</surname><given-names>J</given-names></name><name><surname>Roobol</surname><given-names>MJ</given-names></name><name><surname>Tammela</surname><given-names>TL</given-names></name><name><surname>Ciatto</surname><given-names>S</given-names></name><name><surname>Nelen</surname><given-names>V</given-names></name><name><surname>Kwiatkowski</surname><given-names>M</given-names></name><name><surname>Lujan</surname><given-names>M</given-names></name><name><surname>Lilja</surname><given-names>H</given-names></name><name><surname>Zappa</surname><given-names>M</given-names></name><name><surname>Denis</surname><given-names>LJ</given-names></name><name><surname>Recker</surname><given-names>F</given-names></name><name><surname>Berenguer</surname><given-names>A</given-names></name><name><surname>Maattanen</surname><given-names>L</given-names></name><name><surname>Bangma</surname><given-names>CH</given-names></name><name><surname>Aus</surname><given-names>G</given-names></name><name><surname>Villers</surname><given-names>A</given-names></name><name><surname>Rebillard</surname><given-names>X</given-names></name><name><surname>Kwast</surname><given-names>T</given-names></name><name><surname>Blijenberg</surname><given-names>BG</given-names></name><name><surname>Moss</surname><given-names>SM</given-names></name><name><surname>Koning</surname><given-names>HJ</given-names></name><name><surname>Auvinen</surname><given-names>A</given-names></name></person-group><article-title>Screening and prostate-cancer mortality in a randomized European study</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>1320</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0810084</pub-id><pub-id pub-id-type="pmid">19297566</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleason</surname><given-names>DF</given-names></name></person-group><article-title>Classification of prostatic carcinomas</article-title><source>Cancer Chemother Rep</source><year>1966</year><volume>50</volume><fpage>125</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">5948714</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Pinthus JH, Witkos M, Fleshner NE, Sweet J, Evans A, Jewett MA, Krahn M, Alibhai S, Trachtenberg J (2006) Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 176:979&#x02013;984; discussion 984</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajinikanth</surname><given-names>A</given-names></name><name><surname>Manoharan</surname><given-names>M</given-names></name><name><surname>Soloway</surname><given-names>CT</given-names></name><name><surname>Civantos</surname><given-names>FJ</given-names></name><name><surname>Soloway</surname><given-names>MS</given-names></name></person-group><article-title>Trends in Gleason score: concordance between biopsy and prostatectomy over 15&#x000a0;years</article-title><source>Urology</source><year>2008</year><volume>72</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2007.10.022</pub-id><pub-id pub-id-type="pmid">18279938</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allam</surname><given-names>CK</given-names></name><name><surname>Bostwick</surname><given-names>DG</given-names></name><name><surname>Hayes</surname><given-names>JA</given-names></name><name><surname>Upton</surname><given-names>MP</given-names></name><name><surname>Wade</surname><given-names>GG</given-names></name><name><surname>Domanowski</surname><given-names>GF</given-names></name><name><surname>Klein</surname><given-names>MA</given-names></name><name><surname>Boling</surname><given-names>EA</given-names></name><name><surname>Stilmant</surname><given-names>MM</given-names></name></person-group><article-title>Interobserver variability in the diagnosis of high-grade prostatic intraepithelial neoplasia and adenocarcinoma</article-title><source>Mod Pathol</source><year>1996</year><volume>9</volume><fpage>742</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">8832557</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Descazeaud</surname><given-names>A</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Allory</surname><given-names>Y</given-names></name><name><surname>Burchardt</surname><given-names>M</given-names></name><name><surname>Salomon</surname><given-names>L</given-names></name><name><surname>Chopin</surname><given-names>D</given-names></name><name><surname>Abbou</surname><given-names>C</given-names></name><name><surname>la Taille</surname><given-names>A</given-names></name></person-group><article-title>What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer?</article-title><source>Eur Urol</source><year>2005</year><volume>48</volume><fpage>911</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2005.07.011</pub-id><pub-id pub-id-type="pmid">16140457</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsivian</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Mouraviev</surname><given-names>V</given-names></name><name><surname>Madden</surname><given-names>JF</given-names></name><name><surname>Mayes</surname><given-names>JM</given-names></name><name><surname>Moul</surname><given-names>JW</given-names></name><name><surname>Polascik</surname><given-names>TJ</given-names></name></person-group><article-title>Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy</article-title><source>Urology</source><year>2009</year><volume>74</volume><fpage>1090</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2009.03.043</pub-id><pub-id pub-id-type="pmid">19616835</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orozco</surname><given-names>R</given-names></name><name><surname>O&#x02019;Dowd</surname><given-names>G</given-names></name><name><surname>Kunnel</surname><given-names>B</given-names></name><name><surname>Miller</surname><given-names>MC</given-names></name><name><surname>Veltri</surname><given-names>RW</given-names></name></person-group><article-title>Observations on pathology trends in 62, 537 prostate biopsies obtained from urology private practices in the United States</article-title><source>Urology</source><year>1998</year><volume>51</volume><fpage>186</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/S0090-4295(97)00620-1</pub-id><pub-id pub-id-type="pmid">9495696</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Muntener M, Epstein JI, Hernandez DJ, Gonzalgo ML, Mangold L, Humphreys E, Walsh PC, Partin AW, Nielsen ME (2008) Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53:767&#x02013;775; discussion 775-766</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Sebo TJ, Blute ML (2009) The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol 181:95&#x02013;104; discussion 104</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twillie</surname><given-names>DA</given-names></name><name><surname>Eisenberger</surname><given-names>MA</given-names></name><name><surname>Carducci</surname><given-names>MA</given-names></name><name><surname>Hseih</surname><given-names>WS</given-names></name><name><surname>Kim</surname><given-names>WY</given-names></name><name><surname>Simons</surname><given-names>JW</given-names></name></person-group><article-title>Interleukin-6: a candidate mediator of human prostate cancer morbidity</article-title><source>Urology</source><year>1995</year><volume>45</volume><fpage>542</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1016/S0090-4295(99)80034-X</pub-id><pub-id pub-id-type="pmid">7879350</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wise</surname><given-names>GJ</given-names></name><name><surname>Marella</surname><given-names>VK</given-names></name><name><surname>Talluri</surname><given-names>G</given-names></name><name><surname>Shirazian</surname><given-names>D</given-names></name></person-group><article-title>Cytokine variations in patients with hormone treated prostate cancer</article-title><source>J Urol</source><year>2000</year><volume>164</volume><fpage>722</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(05)67289-8</pub-id><pub-id pub-id-type="pmid">10953133</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>HL</given-names></name><name><surname>McCurdy</surname><given-names>MA</given-names></name><name><surname>Kattan</surname><given-names>MW</given-names></name><name><surname>Timme</surname><given-names>TL</given-names></name><name><surname>Scardino</surname><given-names>PT</given-names></name><name><surname>Thompson</surname><given-names>TC</given-names></name></person-group><article-title>Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma</article-title><source>J Urol</source><year>1999</year><volume>161</volume><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(01)62092-5</pub-id><pub-id pub-id-type="pmid">10037394</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>TC</given-names></name><name><surname>Truong</surname><given-names>LD</given-names></name><name><surname>Timme</surname><given-names>TL</given-names></name><name><surname>Kadmon</surname><given-names>D</given-names></name><name><surname>McCune</surname><given-names>BK</given-names></name><name><surname>Flanders</surname><given-names>KC</given-names></name><name><surname>Scardino</surname><given-names>PT</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name></person-group><article-title>Transforming growth factor beta 1 as a biomarker for prostate cancer</article-title><source>J Cell Biochem Suppl</source><year>1992</year><volume>16H</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1002/jcb.240501212</pub-id><pub-id pub-id-type="pmid">1289674</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truong</surname><given-names>LD</given-names></name><name><surname>Kadmon</surname><given-names>D</given-names></name><name><surname>McCune</surname><given-names>BK</given-names></name><name><surname>Flanders</surname><given-names>KC</given-names></name><name><surname>Scardino</surname><given-names>PT</given-names></name><name><surname>Thompson</surname><given-names>TC</given-names></name></person-group><article-title>Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study</article-title><source>Hum Pathol</source><year>1993</year><volume>24</volume><fpage>4</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/0046-8177(93)90055-L</pub-id><pub-id pub-id-type="pmid">7678092</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eastham</surname><given-names>JA</given-names></name><name><surname>Truong</surname><given-names>LD</given-names></name><name><surname>Rogers</surname><given-names>E</given-names></name><name><surname>Kattan</surname><given-names>M</given-names></name><name><surname>Flanders</surname><given-names>KC</given-names></name><name><surname>Scardino</surname><given-names>PT</given-names></name><name><surname>Thompson</surname><given-names>TC</given-names></name></person-group><article-title>Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer</article-title><source>Lab Invest</source><year>1995</year><volume>73</volume><fpage>628</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">7474936</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>KT</given-names></name><name><surname>Anthony</surname><given-names>CT</given-names></name><name><surname>Steiner</surname><given-names>MS</given-names></name></person-group><article-title>Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate</article-title><source>Prostate</source><year>1997</year><volume>33</volume><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0045(19971001)33:2&#x0003c;133::AID-PROS7&#x0003e;3.0.CO;2-L</pub-id><pub-id pub-id-type="pmid">9316654</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Nuccie</surname><given-names>BL</given-names></name><name><surname>Ritterman</surname><given-names>I</given-names></name><name><surname>Liesveld</surname><given-names>JL</given-names></name><name><surname>Abboud</surname><given-names>CN</given-names></name><name><surname>Ryan</surname><given-names>DH</given-names></name></person-group><article-title>TGF-beta down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors</article-title><source>J Immunol</source><year>1997</year><volume>159</volume><fpage>117</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">9200446</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubinett</surname><given-names>SM</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Dhanani</surname><given-names>S</given-names></name><name><surname>Economou</surname><given-names>JS</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Dougherty</surname><given-names>GJ</given-names></name><name><surname>McBride</surname><given-names>WH</given-names></name></person-group><article-title>Down-regulation of murine fibrosarcoma transforming growth factor-beta 1 expression by interleukin 7</article-title><source>J Natl Cancer Inst</source><year>1995</year><volume>87</volume><fpage>593</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1093/jnci/87.8.593</pub-id><pub-id pub-id-type="pmid">7752257</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blobe</surname><given-names>GC</given-names></name><name><surname>Schiemann</surname><given-names>WP</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><article-title>Role of transforming growth factor beta in human disease</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><fpage>1350</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1056/NEJM200005043421807</pub-id><pub-id pub-id-type="pmid">10793168</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jicha</surname><given-names>DL</given-names></name><name><surname>Mule</surname><given-names>JJ</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy</article-title><source>J Exp Med</source><year>1991</year><volume>174</volume><fpage>1511</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1084/jem.174.6.1511</pub-id><pub-id pub-id-type="pmid">1744582</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naume</surname><given-names>B</given-names></name><name><surname>Espevik</surname><given-names>T</given-names></name></person-group><article-title>Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study</article-title><source>J Immunol</source><year>1991</year><volume>147</volume><fpage>2208</fpage><lpage>2214</lpage><pub-id pub-id-type="pmid">1717551</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>SC</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Kar</surname><given-names>UK</given-names></name><name><surname>Batra</surname><given-names>RK</given-names></name><name><surname>Elashoff</surname><given-names>D</given-names></name><name><surname>Strieter</surname><given-names>RM</given-names></name><name><surname>Dubinett</surname><given-names>SM</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name></person-group><article-title>IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer</article-title><source>J Immunol</source><year>2009</year><volume>182</volume><fpage>6951</fpage><lpage>6958</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803340</pub-id><pub-id pub-id-type="pmid">19454692</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroten-Loef</surname><given-names>C</given-names></name><name><surname>Ridder</surname><given-names>CM</given-names></name><name><surname>Reneman</surname><given-names>S</given-names></name><name><surname>Crezee</surname><given-names>M</given-names></name><name><surname>Dalgleish</surname><given-names>A</given-names></name><name><surname>Todryk</surname><given-names>SM</given-names></name><name><surname>Bangma</surname><given-names>CH</given-names></name><name><surname>Kraaij</surname><given-names>R</given-names></name></person-group><article-title>A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy</article-title><source>Cancer Immunol Immunother</source><year>2009</year><volume>58</volume><fpage>373</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1007/s00262-008-0560-z</pub-id><pub-id pub-id-type="pmid">18641982</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Carlo</surname><given-names>E</given-names></name><name><surname>D&#x02019;Antuono</surname><given-names>T</given-names></name><name><surname>Pompa</surname><given-names>P</given-names></name><name><surname>Giuliani</surname><given-names>R</given-names></name><name><surname>Rosini</surname><given-names>S</given-names></name><name><surname>Stuppia</surname><given-names>L</given-names></name><name><surname>Musiani</surname><given-names>P</given-names></name><name><surname>Sorrentino</surname><given-names>C</given-names></name></person-group><article-title>The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>2979</fpage><lpage>2987</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1951</pub-id><pub-id pub-id-type="pmid">19366834</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriksen</surname><given-names>PJ</given-names></name><name><surname>Dits</surname><given-names>NF</given-names></name><name><surname>Kokame</surname><given-names>K</given-names></name><name><surname>Veldhoven</surname><given-names>A</given-names></name><name><surname>Weerden</surname><given-names>WM</given-names></name><name><surname>Bangma</surname><given-names>CH</given-names></name><name><surname>Trapman</surname><given-names>J</given-names></name><name><surname>Jenster</surname><given-names>G</given-names></name></person-group><article-title>Evolution of the androgen receptor pathway during progression of prostate cancer</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>5012</fpage><lpage>5020</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3082</pub-id><pub-id pub-id-type="pmid">16707422</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heul-Nieuwenhuijsen</surname><given-names>L</given-names></name><name><surname>Dits</surname><given-names>NF</given-names></name><name><surname>Jenster</surname><given-names>G</given-names></name></person-group><article-title>Gene expression of forkhead transcription factors in the normal and diseased human prostate</article-title><source>BJU Int</source><year>2009</year><volume>103</volume><fpage>1574</fpage><lpage>1580</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2009.08351.x</pub-id><pub-id pub-id-type="pmid">19220249</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>AR</given-names></name><name><surname>Motiwala</surname><given-names>HG</given-names></name><name><surname>Karim</surname><given-names>OM</given-names></name></person-group><article-title>The discovery of prostate-specific antigen</article-title><source>BJU Int</source><year>2008</year><volume>101</volume><fpage>5</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2007.07488.x</pub-id><pub-id pub-id-type="pmid">17760888</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shariat</surname><given-names>SF</given-names></name><name><surname>Walz</surname><given-names>J</given-names></name><name><surname>Roehrborn</surname><given-names>CG</given-names></name><name><surname>Zlotta</surname><given-names>AR</given-names></name><name><surname>Perrotte</surname><given-names>P</given-names></name><name><surname>Suardi</surname><given-names>N</given-names></name><name><surname>Saad</surname><given-names>F</given-names></name><name><surname>Karakiewicz</surname><given-names>PI</given-names></name></person-group><article-title>External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>1526</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.12.4669</pub-id><pub-id pub-id-type="pmid">18349404</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svatek</surname><given-names>RS</given-names></name><name><surname>Jeldres</surname><given-names>C</given-names></name><name><surname>Karakiewicz</surname><given-names>PI</given-names></name><name><surname>Suardi</surname><given-names>N</given-names></name><name><surname>Walz</surname><given-names>J</given-names></name><name><surname>Roehrborn</surname><given-names>CG</given-names></name><name><surname>Montorsi</surname><given-names>F</given-names></name><name><surname>Slawin</surname><given-names>KM</given-names></name><name><surname>Shariat</surname><given-names>SF</given-names></name></person-group><article-title>Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence</article-title><source>Prostate</source><year>2009</year><volume>69</volume><fpage>886</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1002/pros.20938</pub-id><pub-id pub-id-type="pmid">19229851</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>KT</given-names></name><name><surname>Anthony</surname><given-names>CT</given-names></name><name><surname>Case</surname><given-names>T</given-names></name><name><surname>Steiner</surname><given-names>MS</given-names></name></person-group><article-title>Transforming growth factor beta as a clinical biomarker for prostate cancer</article-title><source>Urology</source><year>1997</year><volume>49</volume><fpage>151</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/S0090-4295(96)00426-8</pub-id><pub-id pub-id-type="pmid">9000208</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitropoulos</surname><given-names>D</given-names></name><name><surname>Kiroudi</surname><given-names>A</given-names></name><name><surname>Christelli</surname><given-names>E</given-names></name><name><surname>Serafetinidis</surname><given-names>E</given-names></name><name><surname>Zervas</surname><given-names>A</given-names></name><name><surname>Anastasiou</surname><given-names>I</given-names></name><name><surname>Dimopoulos</surname><given-names>C</given-names></name></person-group><article-title>Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue</article-title><source>Urol Res</source><year>2004</year><volume>32</volume><fpage>317</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1007/s00240-003-0360-z</pub-id><pub-id pub-id-type="pmid">15365652</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Nakachi</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Tamakoshi</surname><given-names>A</given-names></name><name><surname>Yagyu</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Inaba</surname><given-names>Y</given-names></name><name><surname>Kazuo</surname><given-names>T</given-names></name></person-group><article-title>Variations in serum transforming growth factor-beta1 levels with gender, age and lifestyle factors of healthy Japanese adults</article-title><source>Dis Markers</source><year>2009</year><volume>27</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">19822955</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porreca</surname><given-names>E</given-names></name><name><surname>Di Febbo</surname><given-names>C</given-names></name><name><surname>Vitacolonna</surname><given-names>E</given-names></name><name><surname>Baccante</surname><given-names>G</given-names></name><name><surname>Di Castelnuovo</surname><given-names>A</given-names></name><name><surname>Angelini</surname><given-names>A</given-names></name><name><surname>Febo</surname><given-names>F</given-names></name><name><surname>Di Nisio</surname><given-names>M</given-names></name><name><surname>Cuccurullo</surname><given-names>F</given-names></name></person-group><article-title>Transforming growth factor-beta1 levels in hypertensive patients: association with body mass index and leptin</article-title><source>Am J Hypertens</source><year>2002</year><volume>15</volume><fpage>759</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1016/S0895-7061(02)02978-3</pub-id><pub-id pub-id-type="pmid">12219869</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vudattu</surname><given-names>NK</given-names></name><name><surname>Magalhaes</surname><given-names>I</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Seyfert-Margolis</surname><given-names>V</given-names></name><name><surname>Maeurer</surname><given-names>MJ</given-names></name></person-group><article-title>Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer</article-title><source>Int J Cancer</source><year>2007</year><volume>121</volume><fpage>1512</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.1002/ijc.22854</pub-id><pub-id pub-id-type="pmid">17546596</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hull</surname><given-names>GW</given-names></name><name><surname>McCurdy</surname><given-names>MA</given-names></name><name><surname>Nasu</surname><given-names>Y</given-names></name><name><surname>Bangma</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Shimura</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>HM</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Albani</surname><given-names>J</given-names></name><name><surname>Ebara</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Timme</surname><given-names>TL</given-names></name><name><surname>Thompson</surname><given-names>TC</given-names></name></person-group><article-title>Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7&#x02013;1 for in situ gene therapy and gene-modified, cell-based vaccines</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>4101</fpage><lpage>4109</lpage><pub-id pub-id-type="pmid">11051263</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selleck</surname><given-names>WA</given-names></name><name><surname>Canfield</surname><given-names>SE</given-names></name><name><surname>Hassen</surname><given-names>WA</given-names></name><name><surname>Meseck</surname><given-names>M</given-names></name><name><surname>Kuzmin</surname><given-names>AI</given-names></name><name><surname>Eisensmith</surname><given-names>RC</given-names></name><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Hall</surname><given-names>SJ</given-names></name></person-group><article-title>IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach</article-title><source>Mol Ther</source><year>2003</year><volume>7</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/S1525-0016(02)00040-0</pub-id><pub-id pub-id-type="pmid">12597906</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Steyerberg</surname><given-names>EW</given-names></name></person-group><source>Clinical prediction models: a practical approach to development, validation, and updating</source><year>2009</year><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name></mixed-citation></ref></ref-list></back></article>